Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Report Code: BIO074B

Publish Date: Mar 2013

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Single User License: $2750

Member Price: FREE

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.

Report Includes

  • An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
  • Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Evaluations of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
  • Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
  • Patent analyses.
  • Comprehensive company profiles of major players.

Report Scope

Current and projected product forecasts during the forecast period of 2012 to 2017 are discussed.  New product launches will be discussed.  Revenue figures for 2011 are actual figures.  Revenue figures for 2012 are actual figures except where actual results have not been reported, due to the timing of the release of the report.

The report includes an analysis of leading and emerging CNS biomarkers and related drugs for each CNS disorder.  Profiles of producers of leading products and their specific products are provided.  The report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment.  The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving CNS biomarker diagnostics and treatment with associated drugs.

Market figures are based on revenues at the manufacturers’ level and are projected at a 2012-dollar value.  Inflation is not computed into the projection figures.  Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.

Included in this report are forecasts by product, product category and by company from 2012 through 2017.  The study is arranged to offer an overview of existing biomarker technology, drug markets for CNS diseases, drug and disease mechanism of action and companies, with forecasts broken down and covered by geographic region or country.

Patent and clinical trial information is reviewed for various candidate biomarkers.  The status of approval by the FDA and regulatory agencies in other countries of biomarker diagnostics in each segment is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change.  Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Analyst Credentials

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.

Let us assist you! Our analysts are ready to tailor this report to your specific need. REACH OUT TO US TODAY

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Central Nervous System (CNS) Biomarkers: Technologies and Global Markets153Free
Chapter- 1: INTRODUCTION5Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW13Free
Chapter- 4: TECHNOLOGIES27Free
Chapter- 5: FACTORS INFLUENCING DEMAND FOR CNS BIOMARKERS35Free
Chapter- 6: GLOBAL PHARMACEUTICAL MARKET7Free
Chapter- 7: CNS PHARMACEUTICAL AND BIOMARKER MARKETS13Free
Chapter- 8: CNS BIOMARKER PIPELINE3Free
Chapter- 9: BIOMARKER INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS6Free
Chapter- 10: CNS BIOMARKER CLINICAL TRIALS9Free
Chapter- 11: PATENT ANALYSIS8Free
Chapter- 12: MERGERS AND ACQUISITIONS, LICENSING AND PARTNERSHIP ACTIVITY IN 20123Free
Chapter- 13: C. CRAMER & CO. GMBH21Free
Published - Oct-2010| Analyst - Munish Das| Code - BIO074A

Report Highlights

  • The global CNS biomarker market was estimated at $1.3 billion in 2009 and is expected to reach close to $3.2 billion by 2015, with a compound annual growth rate (CAGR) of 17.1% from 2010 to 2015.
  • The CNS molecular diagnostic market will see the largest growth, with a compound annual growth rate (CAGR) of 172.3% from 2010 to 2015 due to the number of diagnostic tests that are in the pipeline. This sector is valued at $2 million in 2010 and is expected to be worth $302 million in 2015.
  • The growth rate for the CNS biomarker market for drug development will increase as more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials. This sector is worth an estimated $162 million in 2010 and is expected to reach $355 million in 2015, a 17% compound annual growth rate (CAGR).

Related Reports

Therapies and Biomarkers for Inflammatory Bowel Disease

Published - Jan 2013 | Publisher - Willem Westra | Code - PHM125A

The market for inflammatory bowel disease therapeutics was valued at $4.8 billion in 2011 and should reach $5 billion in 2012. Total market value is expected to reach nearly $6.2 billion in 2017 after increasing at a five-year compound annual growth rate of 4.1%. 

Global Markets for Diabetes Therapeutics and Diagnostics

Published - Jan 2013 | Publisher - Paul Evers | Code - HLC029D

The global market for diabetes therapeutics and diagnostics was valued at $110 billion in 2011 and should reach nearly $118.7 billion in 2012.  Total market value is expected to reach nearly $157 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5.7%.

Biomarkers: Technologies and Global Markets

Published - Mar 2011 | Publisher - Jackson Highsmith | Code - BIO061B

In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate (CAGR) of 19.8%.

Recent Reports

Gene Synthesis: Technologies and Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - BIO251A

The global market for Gene Synthesis is estimated to increase from $2.0 billion in 2023 to reach $4.1 billion by 2028, at a compound annual growth rate (CAGR) of 15.8% from 2023 through 2028.

Flow Cytometry: Products, Technologies and Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - BIO085F

The global market for flow cytometry products is expected to grow from $5.2 billion in 2023 to $8.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2029.

PEGylated Proteins Market

Published - May 2024 | Publisher - BCC Publishing | Code - BIO253A

The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.

Companion Diagnostics: Technologies and Markets

Published - May 2024 | Publisher - BCC Publishing | Code - BIO077F

The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.

Exosome Diagnostics, Therapeutics and Research Tools: Global Markets

Published - May 2024 | Publisher - BCC Publishing | Code - BIO149E

The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.

Top Trending Reports

Global Market for Cell and Gene Therapy

Published - Apr 2024 | Publisher - BCC Publishing | Code - BIO225B

The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028. 

Peptide Synthesis: Global Markets

Published - May 2024 | Publisher - BCC Publishing | Code - BIO252A

The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.

3D Cell Cultures: Technologies and Global Markets

Published - Mar 2024 | Publisher - BCC Publishing | Code - BIO140D

The global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028, at a compound annual growth rate (CAGR) of 26.5% from 2023 through 2028.

Oligonucleotides: Global Markets

Published - Apr 2024 | Publisher - BCC Publishing | Code - BIO220B

The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.

Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets

Published - May 2024 | Publisher - BCC Publishing | Code - HLC078F

The global market for medical magnetic resonance imaging (MRI) is expected to grow from $7.2 billion in 2023 and projected to reach $9.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 6.4% during the forecast period of 2023 to 2028.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
Customize Report